Analysis before buying or selling BB Biotech shares

In order to optimally study the BB Biotech share price, it is necessary to have the necessary knowledge about this listed stock, but also about this company. In this article, we propose that you learn more about this group, including details of its activities and sources of profit, a complete presentation of its competitors on the market, some examples of its recent partnerships and some advice to help you carry out a good fundamental analysis of this stock.

Trade the BB Biotech share!
78% of retail CFD accounts lose money. You should consider whether you can afford to take the high risk of losing your money. This is an advert for trading CFDs on eToro

Elements to consider before selling or buying BB Biotech shares

Analysis N°1

The research and trials carried out by the biotechnology companies in which the group now has a stake are among the elements you should monitor as part of this analysis.

Analysis N°2

We will also follow the group's new investments in new biotechs as well as the disposal of some of its assets from a strategic point of view and to gain profitability.

Analysis N°3

Following the stock market evolution of the companies in which BB Biotech has shares is also essential to speculate on this value.

Analysis N°4

Regulations and legislation enforced by health control authorities are also part of what you should consider when analysing this value as it may influence the activities of biotechs in general.

Analysis N°5

Finally, BB Biotech's financial results should also be followed closely, with its annual and quarterly turnover and the evolution of the quantity of assets it manages.

Trade the BB Biotech share!
78% of retail CFD accounts lose money. This is an advert for trading CFDs on eToro

General presentation of BB Biotech

To improve your knowledge of the BB Biotech share, you must of course be fully familiar with this company. That is why we are now offering you a complete presentation of the company with details of its main activities:

The BB Biotech Group is a Swiss group and more precisely a holding company specialised in the acquisition of shareholdings in biotechnology companies. The group currently holds a portfolio of securities with a market value of approximately CHF 3,064.2 million.

To better understand the sources of income for this group, it is possible to break them down into listed and non-listed companies.

The BB Biotech Group's shareholdings in listed companies alone generate 99.9% of its revenues. The group holds shares in Ionis Pharmaceuticals, which specialises in rare diseases, Gilead Sciences, which specialises in infectious diseases, viral diseases and influenza, Celgene Corporation, which specialises in cancers and immune system inflammation, Esperion Therapeutics, which specialises in cardio-metabolic diseases, Vertex Pharmaceuticals, which specialises in infectious and immune diseases, and Incyte, which specialises in cancers, haematological disorders and inflammatory diseases.

Analysis before buying or selling BB Biotech shares
Trade the BB Biotech share!
78% of retail CFD accounts lose money. This is an advert for trading CFDs on eToro

The major competitors of BB Biotech

In order to make a good analysis of BB Biotech stock, you should also be aware of other similar companies whose shares may compete with this stock.

Federated Hermes

This US investment manager has been in existence since 1955 and currently manages over $575.9 billion in client assets. The firm offers 135 different types of mutual funds covering equities, fixed income, alternative assets, private markets, multi-asset and liquidity strategies and a range of separately managed account strategies. Clients include corporations, government entities, insurance companies, foundations and endowments, banks and brokers, and dealers.

Fortress Investment Group LLC

This other US alternative investment fund offers alternative and traditional investment strategies to institutional and private investors and has been publicly traded since 2007. The group was acquired by SoftBank in 2017.

Cohen & Steers

This global investment manager manages portfolios focused on real assets including real estate, infrastructure and commodities, as well as preferred securities and other income solutions. It serves individual and institutional investors around the world with a wide range of investment vehicles.

Virtus Investment Partners

This company operates a multi-manager asset management business that includes a number of individual affiliated managers, each with their own investment process and brand, as well as the services of unaffiliated sub-advisors.


The major partners of BB Biotech

In addition to knowing BB Biotech's main adversaries well, you should also know its allies. Here, we are talking about the biotech companies in which the group has a stake:

Ionis Pharmaceuticals

A US biotech specialising in the discovery and development of RNA-targeted therapeutics.

Celgene Corporation

A US pharmaceutical company listed on the NASDAQ 100 and based in New Jersey.

Esperion Therapeutics

This US public pharmaceutical company is focused on the development of bempedoic acid, an orally available molecule for lowering LDL-C levels.

Vertex Pharmaceuticals 

An American biotechnology company based in Boston that was founded in 1989 and is now a component of the NASDAQ 100 stock index.

Incyte

Finally, this US pharmaceutical company based in Delaware was founded in 1991 and listed on the stock market in 1993.

Trade the BB Biotech share!
78% of retail CFD accounts lose money. This is an advert for trading CFDs on eToro

Frequently Asked Questions

Who are the largest shareholders in the BB Biotech Group?

Currently, the capital of BB Biotech is divided among several large private shareholders, including Erich Hunziker with 2.63% of the shares, UBS Asset Management Schweiz with 1.44% of the shares, BlackRock Asset Management with 1.16% of the shares, Credit Suisse Asset Management with 1.16% of the shares, Zurcher Kantonalbank with 0.92% of the shares, The Vanguard Group with 0.64% of the shares, Mackenzie Investment Europe with 0.55% of the shares, UBP-Gestion Institutionnelle with 0.52% of the shares, Arca Fondi SGR with 0.4% of the shares and Aberdeen Standard Capital with 0.38% of the shares.

On which stock exchange index is the BB Biotech share listed?

BB Biotech shares are of course listed on the Domestic Standard Market of the Zurich Stock Exchange, the SIX Swiss Exchange. But the company is also part of an important stock market index, the TexDAX, which is a stock market index measuring the performance of the 30 largest German companies in the biotechnology sector. This index used to be called 'SunDax' because it included a large number of companies specialising in the manufacture and sale of solar panels.

How to trade BB Biotech shares online?

For some time now, the BB Biotech Group share has been available for direct online trading via a CFD trading platform. These contracts for difference allow you to take an upward or downward position on this stock without having to actually buy shares in the company.

Trade the BB Biotech share!

eToro is a multi-asset platform which offers both investing in stocks and cryptoassets, as well as trading CFDs.

Please note that CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78% of retail CFD accounts lose money. You should consider whether you can afford to take the high risk of losing your money.

Past performance is not an indication of future results. Trading history presented is less than 5 complete years and may not suffice as basis for investment decision.

Copy trading is a portfolio management service, provided by eToro (Europe) Ltd., which is authorised and regulated by the Cyprus Securities and Exchange Commission.

Cryptoasset investing is unregulated in some EU countries and the UK. No consumer protection. Your capital is at risk.

eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro.